Non-Coding RNA Assays Market Outlook:
Non-Coding RNA Assays Market size was over USD 382.84 million in 2025 and is anticipated to cross USD 1.47 billion by 2035, growing at more than 14.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of non-coding RNA assays is estimated at USD 432.46 million.
The growth of the market can be attributed to the increasing investment in medical research. Further, the need for assays that can accurately detect and quantify ncRNAs is being driven by the increase in research activities that use these molecules, which is also expected to add to the market growth. As of 2018, total U.S. spending on medical and health research and development (R&D) increased by over 6%.
In addition to these, factors that are believed to fuel the market growth of non-coding RNA assays include the surging government initiatives to promote life science research projects. For instance, in life sciences, research initiatives, non-coding RNA (ncRNA) tests have grown in importance, as they provide information on the roles and control mechanisms of ncRNAs in the cell. Additionally, the growing advancements in technology have enabled the development of more sensitive and accurate ncRNA detection assays, which are predicted to present the potential for market expansion over the projected period.
